|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Investments: | ||||||||||||||||||||
| Fixed maturities, available-for-sale, at fair value (Amortized cost: 2025 - $205,909; 2024 - $236,788) | ||||||||||||||||||||
| Equity securities, at fair value (Cost: 2025 - $13,436; 2024 - $13,436) | ||||||||||||||||||||
| Equity method investments | ||||||||||||||||||||
| Other investments (Allowance for expected credit losses: 2025 - $1,023; 2024 - $1,023) | ||||||||||||||||||||
| Total investments | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash and cash equivalents | ||||||||||||||||||||
| Accrued investment income | ||||||||||||||||||||
| Reinsurance balances receivable, net (includes $6,494 and $5,171 from related parties in 2025 and 2024, respectively. Allowance for expected credit losses: 2025 - $203; 2024 - $169) | ||||||||||||||||||||
| Reinsurance recoverable on unpaid losses (Allowance for expected credit losses: 2025 - $849; 2024 - $2,963) | ||||||||||||||||||||
| Net loan receivable from related party | ||||||||||||||||||||
| Deferred commission and other acquisition expenses (includes $4,948 and $7,553 from related parties in 2025 and 2024, respectively) | ||||||||||||||||||||
| Funds withheld receivable (Allowance for expected credit losses: 2025 - $8; 2024 - $8) | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Assets held for sale | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES | ||||||||||||||||||||
| Reserve for loss and loss adjustment expenses (includes $656,022 and $687,274 from related parties in 2025 and 2024, respectively) | ||||||||||||||||||||
| Unearned premiums (includes $25,578 and $29,204 from related parties in 2025 and 2024, respectively) | ||||||||||||||||||||
| Deferred gain on retroactive reinsurance | ||||||||||||||||||||
| Liability for securities purchased | ||||||||||||||||||||
| Accrued expenses and other liabilities (includes $31,647 and $59,096 from related parties in 2025 and 2024, respectively) | ||||||||||||||||||||
| Senior notes - principal amount | ||||||||||||||||||||
| Less: unamortized debt issuance costs | ||||||||||||||||||||
| Senior notes, net | ||||||||||||||||||||
| Liabilities held for sale | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| EQUITY | ||||||||||||||||||||
| Preference shares | ||||||||||||||||||||
| Common shares ($0.01 par value; 2025: 151,310,133 and 2024: 150,298,798 shares issued; 2025: 99,682,710 and 2024: 99,039,253 shares outstanding) | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Treasury Stock, Common, Shares | ||||||||||||||||||||
| Treasury shares, at cost (2025: 51,627,423 shares and 2024: 51,259,545 shares) | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
Loading...
